9.48

2.02% -0.195

After Hours: 9.49 0.010 +0.11%

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $9.48, with a volume of 2.25M. It is down -2.02% in the last 24 hours and up +26.40% over the past month. Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Previous Close:

$9.675

Open:

$9.69

24h Volume:

2.25M

Relative Volume:

0.71

Market Cap:

$1.52B

Revenue:

$68.56M

Net Income/Loss:

$-437.99M

P/E Ratio:

-2.9963

EPS:

-3.1639

Net Cash Flow:

$-396.61M

1W Performance:

-4.05%

1M Performance:

+26.40%

6M Performance:

+97.50%

1Y Performance:

+35.33%

1-Day Range:

$9.44

$9.755

1-Week Range:

$9.12

$10.29

52-Week Range:

$4.155

$10.94

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1114)

Industry

Biotechnology (620)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

367

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	9.48	1.55B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	462.49	118.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	759.05	80.02B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	706.03	43.52B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.42	42.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	287.33	32.13B	5.36B	287.73M	924.18M	2.5229

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Upgrade	Raymond James	Outperform → Strong Buy
Sep-03-25	Initiated	Evercore ISI	Outperform
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

08:01 AM

Guidance Update: What is the Moat Score of Vir Biotechnology IncPortfolio Value Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn

08:01 AM

Mar 14, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 14, 2026

VIR News Today | Why did Vir Biotechnology stock go up today? $VIR - MarketBeat

Mar 14, 2026

Mar 11, 2026

Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis

Mar 11, 2026

Mar 09, 2026

Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN

Mar 09, 2026

VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union

Mar 09, 2026

Mar 07, 2026

Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat

Mar 07, 2026

Mar 06, 2026

HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat

Mar 06, 2026

Mar 05, 2026

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits

Mar 05, 2026

Vir Biotechnology Names CEO Marianne De Backer as President - The Globe and Mail

Mar 05, 2026

Mar 04, 2026

According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget

Mar 04, 2026

Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView

Mar 04, 2026

Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com

Mar 04, 2026

Vir Biotechnology, Inc. Appoints Marianne De Backer as President - marketscreener.com

Mar 04, 2026

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Mar 04, 2026

VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus

Mar 04, 2026

Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st

Mar 04, 2026

Mar 03, 2026